1+ day, 21+ min ago   (323+ words) Last week’s regulatory news saw the US Food and Drug Administration (FDA) grant accelerated approval for AstraZeneca’s Etcamah combination for the treatment of breast cancer. On the research front, Novartis suffered another setback, this time with its Phase III trial…...

4+ day, 22+ hour ago   (230+ words) The Pharma Letter - Kura launches new company, diabetes focused Caspian Therapeutics US biotech Kura Oncology (Nasdaq: KURA) today announced the launch of Caspian Therapeutics, a separately financed company established to advance small-molecule menin inhibitors for diabetes and cardiometabolic diseases. Caspian…...

1+ week, 3+ hour ago   (263+ words) thepharmaletter.com Regulatory round-up: 7 September 2026 Medicines regulators in major international markets have issued a mix of first-in-class approvals, safety reviews, supply and shortage measures, consultations and one authorization suspension over the past week. The latest round-up includes two clearances from…...

2+ week, 6+ day ago   (227+ words) The Pharma Letter - Revier launches with six million euros seed round to develop class IIa HDAC inhibitors for cardiometabolic disease German biotech Revier Therapeutics has launched operations following the close of a six million euros ($6.45 million) seed financing round, the…...

3+ week, 2+ day ago   (588+ words) The Pharma Letter A clinical-stage biopharmaceutical company focused on WEE1 inhibition in biomarker-selected ovarian cancer, with its lead asset azenosertib approaching a pivotal registration-enabling data readout in 2026. Zentalis Pharmaceuticals discovers and develops small molecule therapeutics targeting fundamental biological pathways in cancer....

3+ week, 3+ day ago   (258+ words) The Pharma Letter Edesa Biotech prices $25 million public offering Canada-based Edesa Biotech (Nasdaq: EDSA) has priced an underwritten public offering expected to generate approximately $25 million in gross proceeds. The company’s shares slumped 17.2% to $4.76 following the announcement. The offering includes 3,870,500 common…...

3+ week, 4+ day ago   (260+ words) The Pharma Letter - ALK appoints Jacob Glenting head of Global R&D Danish allergy specialist ALK-Abelló A/S (Nasdaq Copenhagen: ALK B) has appointed Jacob Glenting (pictured above) as executive vice president and head of global R&D, effective September…...

3+ week, 4+ day ago   (243+ words) The Pharma Letter - Kynexis raises 97 million euros to advance med for cognitive disorders Dutch clinical-stage biotech Kynexis today announced the closing of a 40 million euros ($46.3 million) Series A extension bringing total Series A financing to 97 million euros ($110 million). The financing…...

3+ week, 5+ day ago   (160+ words) thepharmaletter.com - Danaher names Julie Sawyer Montgomery as president and CEO This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from…...

3+ week, 5+ day ago   (212+ words) thepharmaletter.com - OmniAb signs $370 million ion channel discovery deal with Eli Lilly California-based antibody discovery technology provider OmniAb (Nasdaq: OABI) has entered a global collaboration and license agreement with US pharma major Eli Lilly (NYSE: LLY) covering a new ion…...